Cell Metabolism
Volume 33, Issue 12, 7 December 2021, Pages 2445-2463.e8
Journal home page for Cell Metabolism

Article
Efferocytosis induces macrophage proliferation to help resolve tissue injury

https://doi.org/10.1016/j.cmet.2021.10.015Get rights and content
Under an Elsevier user license
open archive

Highlights

  • Apoptotic cell degradation after macrophage efferocytosis induces proliferation

  • Apoptotic cell-derived nucleotides trigger a DNA-PK-mTorc2-Myc proliferation pathway

  • Proliferating efferocytic macrophages are pro-resolving in vitro and in vivo

  • Genetic silencing of the proliferation pathway hinders atherosclerosis regression

Summary

Apoptotic cell clearance by macrophages (efferocytosis) promotes resolution signaling pathways, which can be triggered by molecules derived from the phagolysosomal degradation of apoptotic cells. We show here that nucleotides derived from the hydrolysis of apoptotic cell DNA by phagolysosomal DNase2a activate a DNA−PKcs−mTORC2/Rictor pathway that increases Myc to promote non-inflammatory macrophage proliferation. Efferocytosis-induced proliferation expands the pool of resolving macrophages in vitro and in mice, including zymosan-induced peritonitis, dexamethasone-induced thymocyte apoptosis, and atherosclerosis regression. In the dexamethasone-thymus model, hematopoietic Rictor deletion blocked efferocytosing macrophage proliferation, apoptotic cell clearance, and tissue resolution. In atherosclerosis regression, silencing macrophage Rictor or DNase2a blocked efferocyte proliferation, apoptotic cell clearance, and plaque stabilization. In view of previous work showing that other types of apoptotic cell cargo can promote resolution in individual efferocytosing macrophages, the findings here suggest that signaling-triggered apoptotic cell-derived nucleotides can amplify this benefit by increasing the number of these macrophages.

Keywords

macrophage
efferocytosis
macrophage proliferation
inflammation resolution
atherosclerosis
MerTK
Myc
DNase2a
mTORC2/Rictor
Erk1/2 signaling

Data and code availability

  • All data reported in this paper will be shared by the lead contact upon request.

  • This paper does not report original code.

  • Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request

Cited by (0)

5

Present address: Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA

6

Present address: Department of Molecular and Cellular Physiology, LSU Health Shreveport, Shreveport, LA 71130, USA

7

These authors contributed equally

8

Lead contact